Dr. Lia Emma, CoEHAR researcher, participated in the 2024 CORESTA congress in Edinburgh to present the latest findings of the REPLICA project
The CORESTA Congress focuses on fostering discussion and the exchange of knowledge and insights in the science of Tobacco Harm Reduction across various disciplines. The 2024 edition is being held in Edinburgh from October 13 to 17. The CORESTA 2024 theme is “Advancing Tobacco Harm Reduction through Scientific Collaboration.”
Dr. Lia Emma, CoEHAR researcher, led a panel to present the latest results of the Replica project.
At the 2024 CORESTA Congress in Edinburgh, dr. Emma presented the preliminary findings from the REPLICA project, a multicenter initiative aimed at replicating a previous study on the effects of traditional cigarettes and e-cigarettes on the efficacy of the chemotherapy drug cisplatin in head and neck cancer cell lines. Unlike the original research, the Replica team used standardized smoking and vaping machines.
“Our experiments, conducted on head and neck cancer cell lines, did not confirm a reduction in the efficacy of cisplatin when combined with cigarette or e-cigarette extracts” explains dr. Emma. “This contrasts with the original study’s findings, which suggested a synergistic reduction in the chemotherapy’s effectiveness. The presentation highlighted the importance of replicating scientific studies to better understand the implications of smoking and e-cigarette use in cancer patients“.
These results raised questions about discrepancies with previous data and emphasized the need for further investigations to evaluate the impact of cigarette and e-cigarette consumption on cancer treatments. Moreover, the findings underscored the critical importance of using standardized protocols for smoke and vapor generation to ensure consistency and reliability in research outcomes.
